Recovery of sexual function after prostate cancer treatment

Current Opinion in Urology

Volumn 16, Issue 6, 2006, Pages 444-448

  Donatucci, Craig F ^a   Greenfield, Jason M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neuro protection; Penile reconstruction; Radical prostatectomy

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; IMMUNOPHILIN; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL; TACROLIMUS; TADALAFIL; VARDENAFIL;

CANCER THERAPY; CLINICAL TRIAL; DRUG EFFECT; ERECTILE DYSFUNCTION; HUMAN; LAPAROSCOPIC SURGERY; NERVE DEGENERATION; NERVE GRAFT; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PENIS PROSTHESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SURAL NERVE; UNSPECIFIED SIDE EFFECT;

HUMANS; IMPOTENCE; MALE; PENILE ERECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURAL NERVE; UROLOGIC SURGICAL PROCEDURES, MALE;

EID: 33750360356     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000250285.60237.7d     Document Type: Review

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. UT by the numbers. Urology Times, 2006:1.
3. Singer PA, Tasch ES, Stocking C, et al. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 1991; 9:328-334.
4. Sculpher M, Bryan S, Fry P, et al. Patients' preferences for the management of nonmetastatic prostate cancer: discrete choice experiment [see comment]. BMJ 2004; 328:382-385.
5. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293:2648-2653. Concise review of the effects of radical prostatectomy on erection and recovery.
6. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005; 173:1701-1705. Contemporary delineation of urinary and sexual outcomes of radical prostatectomy.
7. Stephenson RA, Mori M, Hsieh YC, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 2005; 174:646-650; discussion 650. Report of the sexual function outcomes from a National Cancer Institute multicenter trial. The comprehensive review of long-term success of treatment options for postsurgical erectile dysfunction, however, suffers from the absence of effective oral therapy during the period under study.
8. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology 2005; 66:83-94. Contemporary outcomes of radical prostatectomy.
9. Rozet F, Galiano M, Cathelineau X, et al. Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J Urol 2005; 174:908-911. Retrospective review of large single center clinical outcomes of laparoscopic prostatectomy.
10. Ghavamian R, Knoll A, Boczko J, et al. Comparison of operative and functional outcomes of laparoscopic radical prostatectomy and radical retropubic prostatectomy: single surgeon experience. Urology 2006; 67:1241-1246. Early report comparing outcomes of LRP to open RRP.
11. Bhandari A, McIntire L, Kaul SA, et al. Perioperative complications of robotic radical prostatectomy after the learning curve. J Urol 2005; 174:915-918. Report of outcomes of robotic prostatectomy with limited information on sexual function.
12. Patel VR, Tully AS, Holmes R, et al. Robotic radical prostatectomy in the community setting - the learning curve and beyond: initial 200 cases. J Urol 2005; 174:269-272. Early report of large single center series of laparoscopic robotic radical prostatectomy.
13. Burnett AL. Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction. J Urol 2003; 170:S31-S34; discussion S34.
14. Montorsi F, Briganti A, Salonia A, et al. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004; 45:123-133.
15. Kim ED, Scardino PT, Hampel O, et al. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol 1999; 161:188-192.
16. Kim ED, Nath R, Slawin KM, et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 2001; 58:983-987.
17. Porpiglia F, Ragni F, Terrone C, et al. Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency? BJU Intl 2005; 95:1267-1271. Report of single center experience performing sural nerve grafts by laparoscopic technique.
18. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial [see comment]. J Urol 1997; 158:1408-1410.
19. Gontero P, Fontana F, Bagnasacco A, et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169:2166-2169.
20. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep 2004; 5:467-471.
21. Gontero P, Kirby R. Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). Prostate Cancer Prostatic Dis 2004; 7:223-226.
22. Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2:532-540; discussion 540-542. Report on the success of sequencing of therapy for postsurgical erectile dysfunction. Supports early use of intracavernosal therapy in patients who are nonresponders to PDE-5 inhibitor therapy early on after radical prostatectomy.
23. Ramsawh HJ, Morgentaler A, Covino N, et al. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol 2005; 174:1395-1398. Report on QoL outcomes for patients with preexisting erectile dysfunction undergoing radical prostatectomy with immediate sexual reconstruction. Results would suggest more aggressive stratification of the degree of preexistent erectile dysfunction would allow proper placement selection of simultaneous prosthesis placement without increasing risks of postoperative complications.
24. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94:2019-2024.
25. Lee M, Doolabh VB, Mackinnon SE, et al. FK506 promotes functional recovery in crushed rat sciatic nerve. Muscle Nerve 2000; 23:633-640.
26. Sezen SF, Hoke A, Burnett AL, et al. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7:1073-1074.
27. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 2004; 171:495-500.
28. Evaluate the effects of GPI 1485 on erectile function following bilateral nerve-sparing prostatectomy. ClinicalTrials.gov. 2006. Web site of trial of now-closed clinical trial of GPI-1485 in prevention of post-surgical erectile dysfunction.
29. A safety and efficacy study of Prograf in the prevention of erectile dysfunction after radical prostatectomy. 2006. Web site of open clinical trial of FK-506 (Prograf) in the prevention of postsurgical erectile dysfunction. Contact information supplied.
30. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 2005; 174:2060-2064. In-vivo study examining neuro-protective effects of EPO in rat model of cavernous injury.